Tuesday, Affymax Inc. (AFFY) closed its underwritten public offering of 4.7 million shares of its common stock, which includes the full exercise of the underwriter's overallotment option of 616,438 shares. The net proceeds to the company after deducting underwriting discounts and commissions and estimated offering expenses are approximately $80.0 million.
Cowen and Company, LLC and Lazard Capital Markets LLC were joint book-runners on the offering and RBC Capital Markets Corp. and Robert W. Baird & Co. Inc. were co-managers for the offering.
Affymax Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.
For comments and feedback: editorial@rttnews.com